Keith Korenchuk counsels and advises global companies on regulatory and compliance matters worldwide, with a focus on compliance program effectiveness, compliance program implementation, operations and evaluation, and related regulatory counseling and advice. He works in a wide variety of industries and sectors including consumer products, electronics, energy, financial services, life sciences, medical device, pharmaceutical, and technology.

Mr. Korenchuk provides regulatory and compliance guidance, advice, and solutions regarding:

  • US and global compliance systems design, implementation, and ongoing assessment;
  • compliance program evaluation under the US Sentencing Guidelines, the UK Bribery Act adequate procedures guidance, the OECD Guidelines on Internal Controls, and related national and international compliance standards;
  • specific compliance program activities including codes of conduct, training program design and delivery, monitoring, and corrective action responses;
  • global anti-bribery legislation, including the US Foreign Corrupt Practices Act, the UK Bribery Act, the Organization for Economic Co-operation and Development (OECD) Anti-bribery Convention, and related national implementing legislation;
  • internal financial controls design, implementation and remediation to institute effective oversight of key risk areas;
  • internal and government initiated investigations;
  • enterprise-wide risk management systems and programs; and
  • global, regional, and country-specific codes of practice and conduct, including industry codes of conduct issued by industry associations.

His work spans many business functions, including research and development, global marketing, sales and marketing, strategic alliances/acquisitions, government affairs, and procurement.

Since 2001, Mr. Korenchuk has been included in The Best Lawyers in America. He has developed, led, and implemented "hands-on" educational and healthcare programs that provide pharmaceuticals and healthcare services, teachers, school supplies, library resources, and computers to indigenous communities in South America for the past 12 years.

Prior Business Experience

Mr. Korenchuk's prior experience includes serving as the CEO of a company that focused on pharmaceutical and healthcare sector compliance, as well as the CEO of a research and development company that focused on homeland security technologies.


  • Serving as an outside compliance expert under a Corporate Integrity Agreement (CIA), providing effectiveness reviews to inform Board of Director's certifications on compliance effectiveness.
  • Assisting a global pharmaceutical company in implementing a revised worldwide compliance program, including program design and structure, code of conduct/policy revision, training, monitoring, auditing, and investigations processes.
  • Providing assistance from a compliance perspective in conjunction with government investigations involving the Foreign Corrupt Practices Act, and development and implementation of related remediation plans.
  • Providing assistance in negotiation of CIAs with the Office of the Inspector General (OIG) of the US Department of Health and Human Services, as well as ongoing support of CIA implementation, ongoing operation, and related OIG site visits.
  • Evaluating regulatory issues and compliance effectiveness in discrete programs and activities, including advisory boards, speaker programs, consulting relationships, investigator sponsored trials, and customer relationship databases.
  • Providing healthcare regulatory advice under the anti-kickback statute for pharmaceutical and medical device companies relating to healthcare professionals.
  • Advising on the application of state marketing and disclosure laws to the operations of pharmaceutical and medical device companies.
  • Assisting pharmaceutical and medical device companies in conducting overall program evaluations for subsidiaries in Europe, the Middle East, Latin America, and Asia, and assisting in remediation efforts.
  • Advising on compliance related issues in interactions with government officials and healthcare professionals on a worldwide basis, including consideration of issues in more than 60 countries.
  • Advising the Board of Directors of a global pharmaceutical and healthcare company on compliance program effectiveness and related governance issues.
  • Evaluating the compliance infrastructure of the research and development division of a pharmaceutical company, making recommendations to enhance the compliance infrastructure, and assisting in the implementation of compliance program enhancements.
  • Assisting pharmaceutical, medical device, and health products companies evaluate and enhance their worldwide due diligence and ongoing compliance oversight of third party agents and distributors.
  • Assisting a medical device company in evaluating its US and global programs, as well as providing implementation advice and assistance.
  • Evaluating the sales and marketing function of a newly acquired business unit for a pharmaceutical company and providing post-closing remediation recommendations and assistance.


Dinner and Roundtable Discussion for the Life Sciences Industry
Arnold & Porter Roundtable Discussion, Shanghai, China
Risk & Compliance Management 2018: United States
Getting the Deal Through
Assessing Halliburton's FCPA Settlement and Lessons Learned (pdf)
Energy Law Report, Vol. 18, No. 2
Navigating Complex Cross-Border Investigations: Focus on the US and Germany
Arnold & Porter Kaye Scholer Webinar
Halliburton's Pursuit of Oil Contracts from Angolan Government Results in $29 Million FCPA Penalty


Best Lawyers
Health Care Law (2001-2019)
Chambers Latin America
Corporate Crime & Investigations (2018-2019)
Fraud & Corporate Investigations (2015-2017)
Latin Lawyer 250
White Collar Crime and Compliance (2018)


  • JD, University of Virginia School of Law
  • MPH, Harvard University
  • BA, Duke University, Phi Beta Kappa
  • District of Columbia

Email Disclaimer